Guizhou Xinbang Pharmaceutical Co., Ltd. is a high-risk China-based Pharmaceuticals company with an ESG score of 35.2. Specializing in medical services and pharmaceutical distribution, the company also focuses on cultivating Chinese herbal medicines, producing Chinese patent medicines, and developing biological drugs.